The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Development of a simple and rapid method for producing non‐fucosylated oligomannose containing antibodies with increased effector function
Abstract
Glycosylation in the Fc region of antibodies has been shown to play an important role in antibody function. In the current study, glycosylation of human monoclonal antibodies was metabolically modulated using a potent α‐mannosidase I inhibitor, kifunensine, resulting in the production of antibodies with oligomannose‐type N‐glycans. Growing Chinese hamster ovary cells for 11 days in batch culture with a single treatment of kifunensine was sufficient to elicit this effect without any significant impact on cell viability or antibody production. Antibodies expressed in the presence of kifunensine at a concentration as low as 60 ng/mL contained mainly oligomannose‐type glycans and demonstrated increased ADCC activity and affinity for FcγRIIIA, but reduced C1q binding. Although the kifunensine‐mediated shift to oligomannose‐type glycans could, in theory, result in rapid clearance of the antibody through increased mannose receptor binding, the serum levels of antibody in mice were not significantly altered up to 168 h following injection. The use of kifunensine provides a simple and rapid method for the production of antibodies with increased ADCC without the time‐consuming need to re‐engineer either the antibody molecule or the host cell line. Biotechnol. Bioeng. 2008;99: 652–665. © 2007 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835
Glycosylation and the Immune System
Rudd, P. M., Elliott, T., Cresswell, P., Wilson, I. A., & Dwek, R. A. (2001) · Science · doi:10.1126/science.291.5512.2370 · Cited by 1,588
Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210665200 · Cited by 1,413
Umaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764
Davies, J., Jiang, L., Pan, L., LaBarre, M. J., Anderson, D., & Reff, M. (2001) · Biotechnology and Bioengineering · doi:10.1002/bit.1119 · Cited by 327
Role of Oligosaccharide Residues of IgG1-Fc in FcγRIIb Binding
Mimura, Y., Sondermann, P., Ghirlando, R., Lund, J., Young, S. P., Goodall, M., & Jefferis, R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107478200 · Cited by 236
The biological activity of human monoclonal IgG anti-D is reduced by β-galactosidase treatment
Kumpel, B. M., Wang, Y., Griffiths, H. L., Hadley, A. G., & Rook, G. A. W. (1995) · Human Antibodies · doi:10.3233/hab-1995-6301 · Cited by 68
Cited by
Glycosylation as a strategy to improve antibody-based therapeutics
Jefferis, R. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2804 · Cited by 829
“Opportunities are also opening up for the generation of synthetic IgG Fc glycoforms that might allow the development of probes to further dissect the complexities of inflammatory responses mediated by the humoral immune syste”
BackgroundAntibody Structure and Function: The Basis for Engineering Therapeutics
Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 638
Terminal sugars of Fc glycans influence antibody effector functions of IgGs
Raju, T. S. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.007 · Cited by 521
Liu, L. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24444 · Cited by 428
Expression systems for therapeutic glycoprotein production
Durocher, Y., & Butler, M. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.10.008 · Cited by 386
The impact of glycosylation on monoclonal antibody conformation and stability
Zheng, K., Bantog, C., & Bayer, R. (2011) · mAbs · doi:10.4161/mabs.3.6.17922 · Cited by 342
Chemoenzymatic Glycoengineering of Intact IgG Antibodies for Gain of Functions
Huang, W., Giddens, J., Fan, S.-Q., Toonstra, C., & Wang, L.-X. (2012) · Journal of the American Chemical Society · doi:10.1021/ja3051266 · Cited by 308
Structure, heterogeneity and developability assessment of therapeutic antibodies
Xu, Y., Wang, D., Mason, B., Rossomando, T., Li, N., Liu, D., Cheung, J. K., Xu, W., Raghava, S., Katiyar, A., et al. (2019) · mAbs · doi:10.1080/19420862.2018.1553476 · Cited by 264
Eon‐Duval, A., Broly, H., & Gleixner, R. (2012) · Biotechnology Progress · doi:10.1002/btpr.1548 · Cited by 234
Yu, M., Brown, D., Reed, C., Chung, S., Lutman, J., Stefanich, E., Wong, A., Stephan, J.-P., & Bayer, R. (2012) · mAbs · doi:10.4161/mabs.20737 · Cited by 203
“Some groups have focused on the addition of small molecule inhibitors of specific reactions along the glycosylation pathway to produce the desired glycoform.(7,9) Finally, many proof of concept studies were conducted with a series of CHO cell lines derived by Stanley using lectin selection, which generated a variety o…”
BackgroundInfluentialModulation of antibody galactosylation through feeding of uridine, manganese chloride, and galactose
Gramer, M. J., Eckblad, J. J., Donahue, R., Brown, J., Shultz, C., Vickerman, K., Priem, P., van den Bremer, E. T. J., Gerritsen, J., & van Berkel, P. H. C. (2011) · Biotechnology and Bioengineering · doi:10.1002/bit.23075 · Cited by 193
Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies
Thomann, M., Reckermann, K., Reusch, D., Prasser, J., & Tejada, M. L. (2016) · Molecular Immunology · doi:10.1016/j.molimm.2016.03.002 · Cited by 179
Wada, R., Matsui, M., & Kawasaki, N. (2019) · mAbs · doi:10.1080/19420862.2018.1551044 · Cited by 186
The choice of mammalian cell host and possibilities for glycosylation engineering
Butler, M., & Spearman, M. (2014) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2014.06.010 · Cited by 175
Glycosylation and Fc Receptors
Hayes, J. M., Cosgrave, E. F. J., Struwe, W. B., Wormald, M., Davey, G. P., Jefferis, R., & Rudd, P. M. (2014) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-319-07911-0_8 · Cited by 110
Glycosylation shapes the efficacy and safety of diverse protein, gene and cell therapies
Rocamora, F., Peralta, A. G., Shin, S., Sorrentino, J., Wu, M. Y. M., Toth, E. A., Fuerst, T. R., & Lewis, N. E. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108206 · Cited by 67
Customized protein glycosylation to improve biopharmaceutical function and targeting
Van Landuyt, L., Lonigro, C., Meuris, L., & Callewaert, N. (2019) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2018.11.017 · Cited by 66
Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®
Lee, C., Jeong, M., Lee, J. J., Seo, S., Cho, S. C., Zhang, W., & Jaquez, O. (2017) · mAbs · doi:10.1080/19420862.2017.1337620 · Cited by 57
Glycoengineering Chinese hamster ovary cells: a short history
Donini, R., Haslam, S. M., & Kontoravdi, C. (2021) · Biochemical Society Transactions · doi:10.1042/bst20200840 · Cited by 37
Metadata
- Authors
- Zhou, Q., Shankara, S., Roy, A., Qiu, H., Estes, S., McVie‐Wylie, A., Culm‐Merdek, K., Park, A., Pan, C., & Edmunds, T.
- Venue
- Biotechnology and Bioengineering
- Publisher
- Wiley
- Published
- 2007-08-06
- Volume
- 99
- Issue
- 3
- Pages
- 652-665
- ISSN
- 0006-3592 (ISSN-L)
- 1097-0290
- OpenAlex
- W2106183724
- Cited by
- 184
- References
- 8
- FWCI
- 2.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.